Medicilon congratulates - Treatable and Accessible! Adult and adolescent Type A and Type B influenza! AnDiCon Bio's pill cures influenza with the new drug Madoxanavir - Phase III successful research

On April 29th, AnDiCon Bio (AnDiCon) announced that the Phase III clinical trial of the new influenza drug Madoxanavir tablets (ADC189), which cures Type A and Type B influenza in adults and adolescents, has reached its primary endpoint, demonstrating excellent safety and efficacy."

Medicilon, as a partner of AnDiCon, provided formulation research services for the 'pediatric version' of the anti-influenza Class 1 Madoxanavir granules for influenza, assisting in its rapid advancement in preclinical research and development processes. This progress of Madoxanavir tablets not only validates its effectiveness and safety in treating influenza in adults and adolescents, but also indicates its enormous potential in the field of influenza treatment in children.

About AnDiCon Bio

The AnDiCon Bio Innovation Team, led by several academicians, focuses on the fields of respiratory anti-infection and pain.  The company has gathered a group of academic professionals and highly efficient and pragmatic senior talents at different stages of new drug development, including innovative drug design and synthesis, DMPK technology research and application, and research and development of high-end formulations suitable for special populations. AnDiCon Bio relies on the company's DMPK platform to establish a new drug R&D system based on metabolic differentiation. In addition to the anti-influenza new drug pipeline ADC189, the company's product pipeline also includes a variety of innovative drugs for respiratory pathogens, such as the anti-respiratory syncytial virus (RSV) drug ADC789 suspension, the novel anti-chlamydia super antibiotic ADC101 suspension, and innovative drugs like ADC308 tablets expected to fill the domestic gap in the treatment of endometriosis and uterine fibroids.  In 2022, the company completed a Pre-A round financing of RMB 100 million. In 2023, the company received strategic investment of tens of millions of RMB from Simcere Pharmaceutical (2096.HK). Since 2024, the company has completed a Series A financing of several hundred million RMB.  Looking forward, the company hopes to obtain more support and empowerment from investment institutions, accelerate the progress of innovative drug research and development, bring new treatment options to patients as soon as possible, and bring Chinese wisdom and solutions that are "healable" and accessible to China's public health security.